Latest real world evidence for Bayer's Xarelto in deep vein thrombosis confirms low rates of major bleeding seen in pivotal trial

German pharma major Bayer (BAYN: DE) and its development partner Janssen Pharmaceuticals, part of US health care giant Johnson & Johnson (NYSE: JNJ) today presented results from two real world studies – the non-interventional XALIA study in patients with deep vein thrombosis (DVT) and a study looking at patients with cancer-associated thrombosis (CAT).

Results from the two studies – on the real world evidence for Xarelto (rivaroxaban) in deep vein thrombosis - were presented at the2015 ASH Annual Meeting, and XALIA findings were also simultaneously published in the Lancet Haematology.

“On average, every 37 seconds someone in the Western world dies from a venous blood clot, so it is important we understand the effectiveness and safety of available treatment options for these potentially life-threatening blood clots in real world patient populations,” said XALIA Principal Investigator Professor Alexander Turpie, McMaster University and Hamilton Health Sciences in Hamilton, Ontario, Canada. “The real world insights from XALIA confirm the positive benefit-risk profile of rivaroxaban for the treatment of deep vein thrombosis that was established in the pivotal EINSTEIN DVT study, endorsing that these pivotal data for rivaroxaban can be translated to the patients physicians typically see in everyday clinical practice,” he added.

In the recently initiated CALLISTO Clinical Research Program Bayer is exploring the potential benefits of rivaroxaban in patients with cancer. The risk of VTE is four times higher in patients with active cancer than in people of the same age without cancer4, with chemotherapy increasing the risk by up to 6.5 times. Blood clots are the leading cause of death in patients with cancer outside the cancer itself.